Joint Effect of Diabetes Mellitus and Hypertension on COVID-19 in-Hospital Mortality Stratified by Age Group and Other Comorbidities: A Cohort Retrospective Study Using Hospital-Based Data in Sleman, Yogyakarta
Abstract
:1. Introduction
2. Materials and Methods
2.1. Study Design and Duration
2.2. Study Setting
2.3. Study Population
2.4. Sample Size and Sampling Technique
2.5. Study Tools and Techniques
2.6. Statistical Analysis
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Li, L.Q.; Huang, T.; Wang, Y.Q.; Wang, Z.P.; Liang, Y.; Huang, T.B.; Zhang, H.Y.; Sun, W.; Wang, Y. COVID-19 patients’ clinical characteristics, discharge rate, and fatality rate of meta-analysis. J. Med. Virol. 2020, 92, 577–583. [Google Scholar] [CrossRef] [PubMed]
- Martins-Filho, P.R.; Antunes de Souza Araújo, A.; Pereira, L.X.; Quintans-Júnior, L.J.; de Souza Barboza, W.; Cavalcante, T.F.; de Souza, M.F.; Góes, M.A.d.O.; Santos, V.S. Factors Associated with Mortality among Hospitalized Patients with COVID-19: A Retrospective Cohort Study. Am. J. Trop. Med. Hyg. 2021, 104, 103–105. [Google Scholar] [CrossRef] [PubMed]
- Dong, E.; Du, H.; Gardner, L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect. Dis. 2020, 20, 533–534. [Google Scholar] [CrossRef]
- Ministry of Health Indonesia. Laporan Nasional Riskesdas 2018; Kemenkes RI: Jakarta, Indonesia, 2018; pp. 154–166. [Google Scholar]
- Albitar, O.; Ballouze, R.; Ooi, J.P.; Ghadzi, S.M.S. Risk factors for mortality among COVID-19 patients. Diabetes Res. Clin. Pract. 2020, 166, 108293. [Google Scholar] [CrossRef]
- Elezkurtaj, S.; Greuel, S.; Ihlow, J.; Michaelis, E.G.; Bischoff, P.; Kunze, C.A.; Sinn, B.V.; Gerhold, M.; Hauptmann, K.; Ingold-Heppner, B.; et al. Causes of death and comorbidities in hospitalized patients with COVID-19. Sci. Rep. 2021, 11, 4263. [Google Scholar] [CrossRef] [PubMed]
- Sun, Y.; Guan, X.; Jia, L.; Xing, N.; Cheng, L.; Liu, B.; Zhang, S.; He, K. Independent and combined effects of hypertension and diabetes on clinical outcomes in patients with COVID-19: A retrospective cohort study of Huoshen Mountain Hospital and Guanggu Fangcang Shelter Hospital. J. Clin. Hypertens. 2021, 23, 218–231. [Google Scholar] [CrossRef]
- Goodman, K.E.; Magder, L.S.; Baghdadi, J.D.; Pineles, L.; Levine, A.R.; Perencevich, E.N.; Harris, A.D. Impact of Sex and Metabolic Comorbidities on Coronavirus Disease 2019 (COVID-19) Mortality Risk Across Age Groups: 66,646 Inpatients Across 613 U.S. Hospitals. Clin. Infect. Dis. 2021, 73, e4113–e4123. [Google Scholar] [CrossRef]
- Lippi, G.; Wong, J.; Henry, B.M. Hypertension and its severity or mortality in Coronavirus Disease 2019 (COVID-19): A pooled analysis. Pol. Arch. Intern. Med. 2020, 130, 304–309. [Google Scholar] [CrossRef] [Green Version]
- Pranata, R.; Lim, M.A.; Huang, I.; Raharjo, S.B.; Lukito, A.A. Hypertension is associated with increased mortality and severity of disease in COVID-19 pneumonia: A systematic review, meta-analysis and meta-regression. J. Renin-Angiotensin-Aldosterone Syst. JRAAS 2020, 21, 1470320320926899. [Google Scholar] [CrossRef]
- Klang, E.; Kassim, G.; Soffer, S.; Freeman, R.; Levin, M.A.; Reich, D.L. Severe obesity as an independent risk factor for COVID-19 mortality in hospitalized patients younger than 50. Obesity 2020, 28, 1595–1599. [Google Scholar] [CrossRef]
- Zhou, X.; Zhu, J.; Xu, T. Clinical characteristics of coronavirus disease 2019 (COVID-19) patients with hypertension on renin-angiotensin system inhibitors. Clin. Exp. Hypertens. 2020, 42, 656–660. [Google Scholar] [CrossRef] [PubMed]
- Wiratama, B.S.; Chen, P.L.; Ma, S.T.; Chen, Y.H.; Saleh, W.; Lin, H.A.; Pai, C.W. Evaluating the combined effect of alcohol-involved and un-helmeted riding on motorcyclist fatalities in Taiwan. Accid. Anal. Prev. 2020, 143, 105594. [Google Scholar] [CrossRef] [PubMed]
- Wiratama, B.S.; Hsu, L.M.; Yeh, Y.S.; Chen, C.C.; Saleh, W.; Liu, Y.H.; Pai, C.W. Joint Effect of Heavy Vehicles and Diminished Light Conditions on Paediatric Pedestrian Injuries in Backover Crashes: A UK Population-Based Study. Int. J. Env. Res. Public Health 2022, 19, 11689. [Google Scholar] [CrossRef] [PubMed]
- Vandenbrouckel, J.P.; von Elm, E.; Altman, D.G.; Gotzsche, P.C.; Mulrow, C.D.; Pocock, S.J.; Poole, C.; Schlesselman, J.J.; Egger, M.; STROBE Initiative. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and elaboration. PLoS Med. 2007, 4, 1628–1655. [Google Scholar]
- Wang, D.; Hu, B.; Hu, C.; Zhu, F.; Liu, X.; Zhang, J.; Wang, B.; Xiang, H.; Cheng, Z.; Xiong, Y. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA 2020, 323, 1061–1069. [Google Scholar] [CrossRef] [PubMed]
- Guan, W.-J.; Ni, Z.-Y.; Hu, Y.; Liang, W.-H.; Ou, C.-Q.; He, J.-X.; Liu, L.; Shan, H.; Lei, C.; Hui, D.S.C.; et al. Clinical characteristics of coronavirus disease 2019 in China. N. Engl. J. Med. 2020, 382, 1708–1720. [Google Scholar] [CrossRef]
- Xu, X.-W.; Wu, X.-X.; Jiang, X.-G.; Xu, K.-J.; Ying, L.-J.; Ma, C.-L.; Li, S.B.; Wang, H.Y.; Zhang, S.; Gao, H.N.; et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: Retrospective case series. BMJ 2020, 368, m606. [Google Scholar] [CrossRef] [Green Version]
- Zhang, J.-J.; Dong, X.; Cao, Y.-Y.; Yuan, Y.-D.; Yang, Y.-B.; Yan, Y.-Q.; Akdis, C.A.; Gao, Y.D. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy 2020, 75, 1730–1741. [Google Scholar] [CrossRef]
- Liu, K.; Fang, Y.-Y.; Deng, Y.; Liu, W.; Wang, M.-F.; Ma, J.-P.; Xiao, W.; Wang, Y.N.; Zhong, M.H.; Li, C.H.; et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. Chin. Med. J. 2020, 133, 1025–1031. [Google Scholar] [CrossRef]
- Huang, C.; Wang, Y.; Li, X.; Ren, L.; Zhao, J.; Hu, Y.; Zhang, L.; Fan, G.; Xu, J.; Gu, X.; et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020, 395, 497–506. [Google Scholar] [CrossRef] [Green Version]
- Emami, A.; Javanmardi, F.; Pirbonyeh, N.; Akbari, A. Prevalence of Underlying Diseases in Hospitalized Patients with COVID-19: A Systematic Review and Meta-Analysis. Arch. Acad. Emerg. Med. 2020, 8, e35. [Google Scholar] [PubMed]
- Saha, S.; Al-Rifai, R.H.; Saha, S. Diabetes prevalence and mortality in COVID-19 patients: A systematic review, meta-analysis, and meta-regression. J. Diabetes. Metab. Disord. 2021, 20, 939–950. [Google Scholar] [CrossRef] [PubMed]
- Indonesia MoH. Main Results of Riskesdas 2018; Kementerian Kesehatan RI: Jakarta, Indonesia, 2018. [Google Scholar]
- Jayaswal, S.K.; Singh, S.; Malik, P.S.; Venigalla, S.K.; Gupta, P.; Samaga, S.N.; Hota, R.N.; Bhatia, S.S.; Gupta, I. Detrimental effect of diabetes and hypertension on the severity and mortality of COVID-19 infection: A multi-center case-control study from India. Diabetes Metab. Syndr. Clin. Res. Rev. 2021, 15, 102248. [Google Scholar] [CrossRef] [PubMed]
- Surendra, H.; Salama, N.; Lestari, K.D.; Adrian, V.; Widyastuti, W.; Oktavia, D.; Lina, R.N.; Djaafara, B.A.; Fadilah, I.; Sagara, R.; et al. Pandemic inequity in a megacity: A multilevel analysis of individual, community and healthcare vulnerability risks for COVID-19 mortality in Jakarta, Indonesia. BMJ Glob. Health 2022, 7, e008329. [Google Scholar] [CrossRef]
- Hernández-Galdamez, D.R.; González-Block, M.Á.; Romo-Dueñas, D.K.; Lima-Morales, R.; Hernández-Vicente, I.A.; Lumbreras-Guzmán, M.; Méndez-Hernández, P. Increased risk of hospitalization and death in patients with COVID-19 and pre-existing noncommunicable diseases and modifiable risk factors in Mexico. Arch. Med. Res. 2020, 51, 683–689. [Google Scholar] [CrossRef]
- Ramphul, K.; Lohana, P.; Ramphul, Y.; Park, Y.; Mejias, S.; Dhillon, B.K.; Sombans, S.; Verma, R. Hypertension, diabetes mellitus, and cerebrovascular disease predispose to a more severe outcome of COVID-19. Arch. Med. Sci. Atheroscler. Dis. 2021, 6, e30–e39. [Google Scholar] [CrossRef]
- Mahamat-Saleh, Y.; Fiolet, T.; Rebeaud, M.E.; Mulot, M.; Guihur, A.; El Fatouhi, D.; Laouali, N.; Peiffer-Smadja, N.; Aune, D.; Severi, G. Diabetes, hypertension, body mass index, smoking and COVID-19-related mortality: A systematic review and meta-analysis of observational studies. BMJ Open 2021, 11, e052777. [Google Scholar] [CrossRef]
- Orioli, L.; Servais, T.; Belkhir, L.; Laterre, P.F.; Thissen, J.P.; Vandeleene, B.; Maiter, D.; Yombi, G.C.; Hermans, M.P. Clinical characteristics and short-term prognosis of in-patients with diabetes and COVID-19: A retrospective study from an academic center in Belgium. Diabetes Metab. Syndr. 2021, 15, 149–157. [Google Scholar] [CrossRef]
- Sonmez, A.; Demirci, I.; Haymana, C.; Tasci, I.; Dagdelen, S.; Salman, S.; Ata, N.; Sahin, I.; Emral, R.; Cakal, E.; et al. Clinical characteristics and outcomes of COVID-19 in patients with type 2 diabetes in Turkey: A nationwide study (TurCoviDia). J. Diabetes 2021, 13, 585–595. [Google Scholar] [CrossRef]
- Chen, Y.; Yang, D.; Cheng, B.; Chen, J.; Peng, A.; Yang, C.; Liu, C.; Xiong, M.; Deng, A.; Zhang, Y.; et al. Clinical Characteristics and Outcomes of Patients With Diabetes and COVID-19 in Association With Glucose-Lowering Medication. Diabetes Care. 2020, 43, 1399–1407. [Google Scholar] [CrossRef]
- Zhou, F.; Yu, T.; Du, R.; Fan, G.; Liu, Y.; Liu, Z.; Xiang, J.; Wang, Y.; Song, B.; Gu, X.; et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet 2020, 395, 1054–1062. [Google Scholar] [CrossRef]
- Maddaloni, E.; Buzzetti, R. Covid-19 and diabetes mellitus: Unveiling the interaction of two pandemics. Diabetes Metab. Res. Rev. 2020, 36, e33213321. [Google Scholar] [CrossRef] [PubMed]
- Tajbakhsh, A.; Gheibi Hayat, S.M.; Taghizadeh, H.; Akbari, A.; inabadi, M.; Savardashtaki, A.; Johnston, T.P.; Sahebkar, A. COVID-19 and cardiac injury: Clinical manifestations, biomarkers, mechanisms, diagnosis, treatment, and follow up. Expert Rev. Anti-Infect. Ther. 2021, 19, 345–357. [Google Scholar] [CrossRef] [PubMed]
- Kotnis, A.; Mittal, R.; Chourasia, N.; Bharti, V.; Singh, S.; Sarkar, P.; Ghosh, A.; Pal, R.; Kanwar, J.R.; Kotnis, A. Blood-based biomarkers for diagnosis, prognosis, and severity prediction of COVID-19: Opportunities and challenges. J. Fam. Med. Prim. Care 2022, 11, 4330–4341. [Google Scholar] [CrossRef]
- Samprathi, M.; Jayashree, M. Biomarkers in COVID-19: An Up-To-Date Review. Front. Pediatr. 2020, 8, 607647. [Google Scholar] [CrossRef]
- Moll-Bernardes, R.; de Sousa, A.S.; Macedo, A.V.S.; Lopes, R.D.; Vera, N.; Maia, L.C.R.; Feldman, A.; Arruda, G.D.A.S.; Castro, M.J.C.; Pimentel-Coelho, P.M.; et al. IL-10 and IL-12 (P70) Levels Predict the Risk of Covid-19 Progression in Hypertensive Patients: Insights From the BRACE-CORONA Trial. Front. Cardiovasc. Med. 2021, 8, 702507. [Google Scholar] [CrossRef]
Characteristics | Deceased n (%) | Discharged Alive n (%) | Total n (%) |
---|---|---|---|
Case’s age | 59.93 ± 15.25 | 46.52 ± 20.98 | 48.31 ± 20.81 |
Case’s age group | |||
71+ years 61–70 years 51–60 years 41–50 years 31–40 years 21–30 years 11–20 years 0–10 years | 93 (26.12) 99 (19.34) 92 (15.06) 45 (11.19) 23 (6.50) 14 (4.91) 1 (1.89) 2 (0.98) | 263 (73.88) 413 (80.66) 519 (84.94) 357 (88.81) 331 (93.50) 271 (95.09) 52 (98.11) 202 (99.02) | 356 (12.82) 512 (18.44) 611 (22.00) 402 (14.48) 354 (12.75) 285 (10.26) 53 (1.91) 204 (7.35) |
Case’s gender | |||
Male Female | 196 (14.39) 173 (12.21) | 1166 (85.61) 1244 (87.79) | 1362 (49.01) 1417 (50.99) |
Diabetes mellitus (DM) | |||
Yes No | 182 (27.70) 187 (8.81) | 475 (72.30) 1935 (91.19) | 657 (23.64) 2122 (76.36) |
Hypertension (HT) | |||
Yes No | 195 (25.93) 174 (8.58) | 557 (74.07) 1853 (91.42) | 752 (27.06) 2027 (72.94) |
Heart disease | |||
Yes No | 46 (30.07) 323 (12.30) | 107 (69.93) 2303 (87.70) | 153 (5.51) 2626 (94.49) |
Kidney disease | |||
Yes No | 56 (36.36) 313 (11.92) | 98 (63.64) 2312 (88.08) | 154 (5.54) 2625 (94.96) |
Asthma | |||
Yes No | 12 (13.48) 357 (13.27) | 77 (86.52) 2333 (86.73) | 89 (3.20) 2690 (96.80) |
Stroke | |||
Yes No | 46 (40.71) 323 (12.12) | 67 (59.29) 2343 (87.88) | 113 (4.07) 2666 (95.93) |
Obesity | |||
Yes No | 12 (26.67) 357 (13.06) | 33 (73.33) 2377 (86.94) | 45 (1.62) 2734 (98.38) |
COPD | |||
Yes No | 15 (31.91) 354 (12.96) | 32 (68.09) 2378 (87.04) | 47 (1.69) 2732 (98.31) |
HIV | |||
Yes No | 2 (22.22) 367 (13.25) | 7 (77.78) 2403 (86.75) | 9 (0.32) 2770 (99.68) |
Tuberculosis | |||
Yes No | 11 (21.15) 358 (13.13) | 41 (78.85) 2369 (86.87) | 52 (1.87) 2727 (98.13) |
COVID-19 Wave | |||
Delta Wave Non-Delta Wave | 306 (14.32) 63 (9.81) | 1831 (85.68) 579 (90.19) | 2137 (76.90) 642 (23.10) |
Length of stay (days) | 6.98 ± 5.97 | 8.23 ± 4.09 | 8.06 ± 4.40 |
Length of stay category | |||
≤4 days >4 days | 174 (35.51) 195 (8.52) | 316 (64.49) 2094 (91.48) | 490 (17.63) 2289 (82.37) |
Hospitals | |||
Sleman District Public Hospital UGM Academic Hospital | 131 (13.66) 238 (13.08) | 828 (86.34) 1582 (86.92) | 959 (34.51) 1820 (65.49) |
Characteristics | Bivariate Analysis | Multivariate Analysis | ||
---|---|---|---|---|
Case’s age group | OR | 95% CI | AOR | 95% CI |
71+ years 61–70 years 51–60 years 41–50 years 31–40 years 21–30 years 11–20 years 0–10 years | 35.72 24.21 17.90 12.73 7.02 5.22 1.94 1 | 8.70–146.68 5.91–99.16 4.37–73.35 3.06–53.03 1.64–30.08 1.17–23.22 0.17–21.84 | 20.09 14.19 12.75 11.66 6.82 6.67 2.87 1 | 4.76–84.75 3.37–59.82 3.03–53.64 2.73–49.85 1.55–30.01 1.46–30.49 0.25–33.59 |
Case’s gender | ||||
Male Female | 1.21 * 1 | 0.96–1.51 | 0.96 1 | 0.74–1.25 |
Diabetes mellitus | ||||
Yes No | 3.96 1 | 3.13–5.00 | 2.93 | 2.22–3.86 |
Hypertension | ||||
Yes No | 3.73 1 | 2.95–4.69 | 2.06 1 | 1.56–2.73 |
Heart disease | ||||
Yes No | 3.06 1 | 2.07–4.46 | 1.74 1 | 1.13–2.67 |
Kidney disease | ||||
Yes No | 4.22 1 | 2.92–6.05 | 3.22 1 | 2.11–4.90 |
Asthma | ||||
Yes No | 1.02 1 | 0.49–1.90 | ||
Stroke | ||||
Yes No | 4.98 1 | 3.28–7.49 | 2.98 1 | 1.86–4.76 |
Obesity | ||||
Yes No | 2.42 1 | 1.13–4.86 | 2.36 1 | 1.10–5.07 |
COPD | ||||
Yes No | 3.15 1 | 1.57–6.05 | 3.11 1 | 1.51–6.39 |
HIV | ||||
Yes No | 1.87 1 | 0.19–9.85 | ||
Tuberculosis | ||||
Yes No | 1.78 1 | 0.82–3.56 | 2.63 1 | 1.25–5.57 |
COVID-19 Wave | ||||
Delta Wave Non-Delta Wave | 1.54 1 | 1.15–2.08 | 1.27 1 | 0.92–1.77 |
Length of stay category | ||||
≤4 days >4 days | 5.91 1 | 4.63–7.53 | 8.85 1 | 6.67–11.73 |
Hospitals | ||||
Sleman District Public Hospital UGM Academic Hospital | 1.05 1 | 0.84–1.32 |
Interaction Term a | AOR | p-Value | 95% CI |
---|---|---|---|
All age group Have DM and HT Have DM but not HT Have HT but not DM Age 0–60 years Have DM and HT Have DM but not HT Have HT but not DM Age 61–71+ years Have DM and HT Have DM but not HT Have HT but not DM No other comorbidities and aged 0–60 years Have DM and HT Have DM but not HT Have HT but not DM No other comorbidities and aged 61–71+ years Have DM and HT Have DM but not HT Have HT but not DM | 5.99 3.25 2.27 9.77 4.68 1.93 4.10 2.06 2.45 12.71 6.72 2.54 6.35 3.41 3.52 | <0.001 <0.001 <0.001 <0.001 <0.001 0.026 <0.001 0.014 <0.001 <0.001 <0.001 0.003 <0.001 0.001 <0.001 | 4.19–8.59 2.21–4.79 1.57–3.28 5.88–16.23 2.76–7.94 1.08–3.45 2.45–6.86 1.15–3.67 1.48–4.06 6.84–23.59 3.57–12.64 1.21–5.33 3.21–12.56 1.71–6.82 1.82–6.81 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Ghilari, Y.E.D.; Iskandar, A.; Wiratama, B.S.; Hartopo, A.B. Joint Effect of Diabetes Mellitus and Hypertension on COVID-19 in-Hospital Mortality Stratified by Age Group and Other Comorbidities: A Cohort Retrospective Study Using Hospital-Based Data in Sleman, Yogyakarta. Healthcare 2022, 10, 2103. https://doi.org/10.3390/healthcare10102103
Ghilari YED, Iskandar A, Wiratama BS, Hartopo AB. Joint Effect of Diabetes Mellitus and Hypertension on COVID-19 in-Hospital Mortality Stratified by Age Group and Other Comorbidities: A Cohort Retrospective Study Using Hospital-Based Data in Sleman, Yogyakarta. Healthcare. 2022; 10(10):2103. https://doi.org/10.3390/healthcare10102103
Chicago/Turabian StyleGhilari, Yampa Eksa Daidella, Arik Iskandar, Bayu Satria Wiratama, and Anggoro Budi Hartopo. 2022. "Joint Effect of Diabetes Mellitus and Hypertension on COVID-19 in-Hospital Mortality Stratified by Age Group and Other Comorbidities: A Cohort Retrospective Study Using Hospital-Based Data in Sleman, Yogyakarta" Healthcare 10, no. 10: 2103. https://doi.org/10.3390/healthcare10102103